Bone Biologics Corp reports results for the quarter ended in March - Earnings Summary

Bone Biologics

15/05/2024 01:05

* Bone Biologics Corp  BBLG.OQ  reported a quarterly
adjusted loss
of $1.31​​ per share for the quarter ended in March, higher than
the same quarter last year, when the company reported EPS of
$-55.20.  The lone analyst forecast for the quarter was for a
loss of $7.60 per share. 
    * Reported revenue was zero​; analysts expected zero. 
    * Bone Biologics Corp's reported EPS for the quarter was a
loss of
$1.31​.
    * Bone Biologics Corp shares had fallen by 10.8% this
quarter and
lost 58.0% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * 
    * Wall Street's median 12-month price target for Bone
Biologics
Corp is $19.50 

This summary was machine generated from LSEG data May 15 at
12:05 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -7.60          -1.31          Beat
 Dec. 31 2023      -5.60          -2.47          Beat
 Sep. 30 2023      -24.32         -4.88          Beat
 Jun. 30 2023      -12.00         -3.84          Beat